Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by rebob313on Apr 19, 2021 11:47am
115 Views
Post# 33022009

Long term potential is huge

Long term potential is huge

 

Therma Bright receives CE certification for AcuVid

 

2021-04-19 08:20 PT - News Release

 

Mr. Rob Fia reports

THERMA BRIGHT ANNOUNCES EU-CE APPROVAL FOR ACUVID(TM) COVID-19 RAPID ANTIGEN SALIVA TEST AND CONDITIONAL SALE FOR 100,000 CE-ONLY ACUVID(TM) TEST KITS

Therma Bright Inc. has received CE approval certification from an EU competent authority of Belgium for its AcuVid COVID-19 rapid antigen saliva test, and has secured a conditional purchase order for 100,000 units through a new global distribution partner, McWilliams Collective.

EU-CE Approval: The EU-CE approval enables Therma Bright to distribute throughout 27 member states that make up the European Union. EU & EEA Member countries that have a combined population of 446,824,564. According to the European Centre for Disease Prevention and Control, as of the 1st week of April over 26.3 million cases have been reported in the EU/EEA since the global pandemic began. The EU declaration of conformity indicates that the AcuVid COVID-19 Rapid Antigen Saliva Test complies with all the requirements of European IVDD (in-vitro diagnostic device) legislation.

According to EU recommendations, timely and accurate COVID-19 testing is an essential part of the management of COVID-19 for slowing down the spread of the virus, supporting decisions on infection control strategies, patient management at healthcare facilities, and detecting asymptomatic cases that could spread the virus further if not isolated.

"The CE regulatory approval is a huge win for Therma Bright and our AcuVid COVID-19 Rapid Antigen Saliva Test. This gives our Company immediate access to the large population of citizens across the European Union," explained Rob Fia, CEO of Therma Bright. "Securing CE approval also gives us access to the UK market and the recommendation by the European Commission favorably positions our innovative 15-minute rapid antigen saliva test to meet the tremendous demand for reliable, accurate and user-friendly tests. We are extremely pleased to partner with the team at McWilliams Collective for this initial 100,000-unit order for the European market, which we expect will be the start of great business relationship."

<< Previous
Bullboard Posts
Next >>